India, March 4 -- Vivoryon Therapeutics N.V., in an update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer's Disease, said that the study did not meet its primary and key secondary endpoints.
VIVIAD is a state-of-the-art Phase 2b study conducted in Europe and designed to evaluate the safety, tolerability, and efficacy of varoglutamstat in 259 participants with mild cognitive impairment (MCI) and mild Alzheimer's Disease.
The company noted that the study did not meet its primary endpoint and did not show a statistically significant difference in change over time on cognition, as measured by a combined score (Z-score) of the Detection test, the Identification test and the 'One Back' test of the Cogstate neuropsychological test...